Overview

Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

Status:
Recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

This is a phase II, single arm, open-label study of two parallel cohorts (advanced stomach and gastroesophageal junction cancer and hepatocellular carcinoma), evaluating the effects of telatinib in combination with Keytruda on progression-free survival.

Phase:

Phase 2

Details

Lead Sponsor:

Andrew Hendifar, MD

Collaborator:

EOC Pharma

Treatments:

Pembrolizumab